Based on our research, the claim that China recovered from the coronavirus without a vaccine is PARTLY FALSE. China has succeeded in its efforts to control the spread of COVID-19 within its borders in large part due to the speed and strictness of its measures. But it has also used vaccines, and actually began vaccinating large swaths of the population before the rest of the world. Just one company has already vaccinated 1 million citizens.
In a decree signed by Health Minister Terawan Agus Putranto on Dec. 3, the government has stipulated that the vaccines that can be used for vaccination programs in Indonesia must come from local pharmaceutical company PT Bio Farma, United Kingdom-based AstaZeneca, China’s Sinopharm or Sinovac Biotech, or US pharma Moderna. The vaccine being jointly produced by US firm Pfizer and German company BioNTech also made the list.
This is not just a sweet talk forum.Everybody are freely to give opinion.Can check back what that bloody moron write to others people who against him.
If you dont want to read just ignored.Maybe others will take benefits either it is bad or good info.
If you invest in stock,there are alwats 2 principle.1 fundamental.2 technical.
Fundamentally kanger is already OUT by looking at qr and worthsly never mention about vaccine planning pun.
Technically as mention last week support price is 18 cents.Already broke.but due to sentiment,buyer came in.
Thirdly,insider already disposed a big amount of his shares.Actually almost 70% volume on Friday was belongs to him.Why he disposed it at 17.5 cents if he can disposed higher.The more accurate reason is,this area of price is already higher.remember,kanger is penny stock standard price is below 10 cents.
Fourthly,the more share float in open market is not a good indicator.Means operator need to use more money to accumulate and spark the price.Malaysian market is very small.All can be manipulated.But before manipulate,operator need to accumulate shares first.And this must be done together with insider/company owner.Now insider disposed,not accumulate.
Fifth,news and article is not pro to Kanger pun.Its mostly about Sinopharm.Now do government require Sinopharm?If yes,insider,politician,KKM family members already bought a lot of shares and it shud above 21.5 cents now.That is the basic.People who know the real story already accumulate.Now do insider accumulate.NO..insider disposing not just small portion,he is disposing almost all hia shares.
Finally,this is free forum.Im using moron to promoter because he is using word dick first.
Your money is your own responsibility.Study before buying stock.Adiooosss...Kekekeke
#Bought kanger 32 but CL at 28.5.Bought back 14/14.5 sold 19.Bought 18 sold above 20.After all 2 round profits,1 round cut loss.Kekekeke
So those buying here will become new owner? How you will ensure Kanger become successful vaccine distributor? Losing money bamboo business how to turnaround?
Good morning. After full of vaccines news flooded the forum in the past 2 days. Today start a new week. today up or down. more important. no point talk about the past. past is a history lah. correct?
look like Sinovax beat Sinopharm to capture oversea market with brazil and Indonesia big shipments. Msia also no confirm shipment from Sinopharm Sinovax or CanSino yet. only conducting trial on another china vaccine. correct?
Malaysia will not allow ANY vaccine to be imported until approved by NPRA. So far, none approved yet. Many countries take risks cos their Covid19 cases very high. Malaysia still can wait as its cases is low.
Who’s who in Covid-19 vaccine play A growing number of Bursa-listed companies have entered into manufacturing and distribution deals BY AMIR IMRAN HUSAIN SAFRI
sunbiz@thesundaily.com
PETALING JAYA: The ongoing Covid-19 pandemic has dictated the performance of the global economy for the majority of 2020. In the early days of the novel coronavirus outbreak, there were a number of companies that jumped on the glove-manufacturing bandwagon, and now with positive news on vaccine development, several more Bursa Malaysia-listed companies are entering the vaccine manufacturing and distribution business.
Making the list of Bursa-listed companies in the vaccine effort is Kanger International Bhd, which joined the foray in September via an agreement with Shenzhen Public Health Technology Co Ltd to secure a dealership/distributorship from China National Pharmaceutical Group Corp’s (Sinopharm) potential vaccine.
Since its initial announcement, the group has entered into two separate agreements with Zuellig Pharma Sdn Bhd and K-Star Sport Ltd for the distribution of Covid-19 vaccine in Malaysia and subsequently received no objections by the Science, Technology and Innovation Ministry (Mosti) for the purchase of vaccine for private sector use in the country.
Similarly, Metronic Global Bhd entered into a memorandum of agreement with Taiwan-listed pharmaceutical company, Medigen Vaccine Biologics Corp for its Covid-19 vaccine, via its subsidiary, Metronic Medicare Sdn Bhd.
Before the group can commence the distributorship, it has to secure a pharmaceutical good distribution practice certification with the National Pharmaceutical Regulatory Agency and register the product with the agency, which entails a full evaluation of the vaccine, including local clinical trials. It expects to submit the documents by 2022/2023.
From the vaccine, Metronic has projected an estimated gross profit of RM120 million to RM180 million based on a price assumption of US$50 per dose and an estimated industry wide gross margin of 20% to 30%.
Bintai Kinden Corp entered into a framework agreement for the development and commercialisation of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China with Chinese Center for Disease Control and Prevention (China CDC), Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co Ltd via its partner, Generex Biotechnology Corp in November.
Subsequently, Generex has signed a US$50 million licensing and development deal for the exclusive use of its vaccine platform technology for infectious disease and cancer in China and its territories.
Under the agreement , Bintai is granted exclusive rights to distribute, sell and commercialise the Covid-19 vaccine in Malaysia, Brunei, Myanmar, Cambodia, Timor-Leste, Indonesia, Laos, the Philippines, Singapore, Thailand and Vietnam. It also has the right of first refusal to commercially exploit the vaccine in New Zealand, Australia and the global halal market.
Ho Wah Genting has also ventured into vaccine play through its collaboration with US-based E-MO Biology Inc (EBI). In November, its vaccine received approval by the US Food & Drug Administration to begin phase IV clinical trials.
The group has also entered into a memorandum of understanding with China’s Xinkexian (Beijing) Biotechnology Co Ltd to appoint the latter as a non-exclusive manufacturer for the vaccine related to the Covid-19 virus, which is contingent on EBI’s successful completion of clinical trials.
DKSH Holdings (Malaysia) Bhd, too, is seen as a possible beneficiary of the vaccine development play, due to its long-term relationships with AstraZeneca and Pfizer, which are front runners in the global vaccine race. Given its established links with the two front runners, there is a probability that the group will be involved in its distribution when the vaccine becomes commercially available.
Similarly, government-linked counters, Pharmaniaga Bhd and Duopharma Biotech Bhd have been identified by the government as pharmaceutical players with the capacity to undertake fill-finish processing for any Covid-19 vaccine.
Given the scale of the pandemic, MIDF Research’s head of research Imran Yassin believes the vaccine will not be reduced to one or two types coming from one or two players.
“Here, we believe that it is a case of more is better. In terms of involvement, again we believe that there will not be one type of involvement which is the best,” he told SunBiz.
Imran opined that any involvement in the value chain will be critical as this is a health crisis, first and foremost.
China vaccine already used internally-result good? Look at China cases statistic yourself. Russia/American vaccine how?? Cases increase!!! Collect now b4 approval.
TA wise, it should take on 0.195 & 0.215 again. A clean breakout from here will see it filling the gap btwn 0.22 - 0.235 to resume the uptrend :-) [Disclaimer: TAYOR]
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
my2020
80 posts
Posted by my2020 > 2020-12-06 22:53 | Report Abuse
https://www.businessinsider.com/china-has-started-rollout-covid-19-vaccines-emergency-access-2020-12